Concord Biotech (NSE:CONCORDBIO) Cash-to-Debt : N/A (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Concord Biotech's cash to debt ratio for the quarter that ended in Dec. 2024 was N/A.

The historical rank and industry rank for Concord Biotech's Cash-to-Debt or its related term are showing as below:

NSE:CONCORDBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.25 Med: 5.74 Max: 92.97
Current: 92.97

During the past 5 years, Concord Biotech's highest Cash to Debt Ratio was 92.97. The lowest was 2.25. And the median was 5.74.

NSE:CONCORDBIO's Cash-to-Debt is ranked better than
77.06% of 1482 companies
in the Biotechnology industry
Industry Median: 7.69 vs NSE:CONCORDBIO: 92.97

Concord Biotech Cash-to-Debt Historical Data

The historical data trend for Concord Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Concord Biotech Cash-to-Debt Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

3.86

2.25

2.59

5.74

29.32

Concord Biotech Quarterly Data
	Mar20	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial								N/A	29.32	N/A	92.97	N/A

Competitive Comparison of Concord Biotech's Cash-to-Debt

For the Biotechnology subindustry, Concord Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Concord Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Concord Biotech's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2855.328	/	(78.506	+	18.87)
	=	29.32

Concord Biotech's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Concord Biotech (NSE:CONCORDBIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Concord Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (NSE:CONCORDBIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

543960:India

Address

Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines